Browse by category

Two separate studies have report that GLP-1s are linked to fewer alcohol and substance related hospitalisations for people with alcohol or substance use dependence. In the first study, published in The Lancet Psychiatry, people with type 2 diabetes were hospitalised less frequently for alcohol or substance use disorders while undergoing treatment with GLP-1 receptor agonists, according to a large Swedish registry study involving the Central Institute of Mental Health (CIMH).

Adolescents and young adults in the US are increasingly using popular GLP-1 weight-loss drugs alone or in conjunction with metabolic and bariatric surgery (MBS) to manage obesity, according to a study by UT Southwestern Medical Center (UTSW) researchers. Severe obesity among adolescents and young adults has increased substantially over the past two decades, currently affecting about 9% of people ages 12 to 18. Among adults, the rate of severe obesity increased from 5% to 10%.

Fractyl Health has announced positive one-year results from its REMAIN-1 Midpoint Cohort, reinforcing the potential of the Revita DMR System (Revita) to be the first durable procedural therapy for post-GLP-1 weight maintenance. The key findings include: Dose-dependent durability confirmed at one year: In the full modified intention-to-treat (mITT) population (N=45), a single Revita procedure reduced weight regain by approximately 40% versus sham at one year (least-squares mea

The popularity of GLP-1 drugs has created a new generation of body contouring patients and a new set of challenges for plastic surgeons, according to a study from Duke University School of Medicine, which suggests that how much weight patients lose - and how fast - could affect surgical results to tighten or remove excess skin after massive weight loss. The study found that massive or rapid weight loss prior to abdominal body contouring surgery is predictive of postoperative

Dr Joe Northup, Associate Professor of Surgery at Vanderbilt University School of Medicine and Director of Metabolic and Bariatric Surgery at Vanderbilt University Medical Center in Nashville, TN, has been elected the 40th president of the American Society for Metabolic and Bariatric Surgery (ASMBS), the nation’s largest professional organisation of metabolic and bariatric surgeons and integrated health professionals dedicated to the treatment of obesity and related diseases.

Despite substantial weight loss, most obesity drugs such as Wegovy and Mounjaro do not meaningfully improve quality of life, and few show cardiovascular benefits at one year, according to an analysis of the latest evidence published by The British Medical Journal (BMJ). More weight loss is also generally accompanied by greater harms, including stomach and bowel symptoms, fatigue and loss of lean (muscle) mass, and improvements are not sustained after stopping treatment. Sever